A Biopsychosocial Model for the Management of Patients With Sickle-Cell Disease Transitioning to Adult Medical Care

Advances in Therapy

Volumn 32, Issue 4, 2015, Pages 293-305

  Crosby, Lori E ^a,b   Quinn, Charles T ^a,b   Kalinyak, Karen A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Adolescent; Pediatric; Sickle cell disease; Transition to adult care; Young adult

Indexed keywords

ADULT; AGE; ANALGESIA; ANEMIA, SICKLE CELL; CHILD; COMPLICATION; DISEASE MANAGEMENT; HEALTH INSURANCE; HUMAN; HUMAN RELATION; INSURANCE; LIFE EXPECTANCY; MEDICATION COMPLIANCE; MORTALITY; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PRIMARY HEALTH CARE; PSYCHOLOGY; SOCIAL WORK; TRANSITION TO ADULT CARE;

ADULT; AGE FACTORS; ANEMIA, SICKLE CELL; CHILD; DISEASE MANAGEMENT; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; INTERPERSONAL RELATIONS; LIFE EXPECTANCY; MEDICATION ADHERENCE; PAIN MANAGEMENT; PATIENT CARE TEAM; PRIMARY HEALTH CARE; SOCIAL WORK; TRANSITION TO ADULT CARE;

EID: 84936928610     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0197-1     Document Type: Review

References (70)

1. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999–2009). Pediatr Blood Cancer. 2013;60:1482–6.
2. Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep. 2013;128:110–6.
3. Yanni E, Grosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983–2002. J Pediatr. 2009;154:541–5.
4. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512–21.
5. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447–52.
6. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001;357:680–3.
7. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol. 1991;28:220–6.
8. Streetly A, Latinovic R, Hall K, Henthorn J. Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005–7. J Clin Pathol. 2009;62:26–30.
9. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314:1593–9.
10. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121:562–9.
11. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645–51.
12. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354–63.
13. Jordan L, Swerdlow P, Coates TD. Systematic review of transition from adolescent to adult care in patients with sickle cell disease. J Pediatr Hematol Oncol. 2013;35:165–9.
14. DeBaun MR, Telfair J. Transition and sickle cell disease. Pediatrics. 2012;130:926–35.
15. Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I. Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol. 2011;86:116–20.
16. Lebensburger JD, Bemrich-Stolz CJ, Howard TH. Barriers in transition from pediatrics to adult medicine in sickle cell anemia. J Blood Med. 2012;3:105–12.
17. Okumura MJ, Heisler M, Davis MM, Cabana MD, Demonner S, Kerr EA. Comfort of general internists and general pediatricians in providing care for young adults with chronic illnesses of childhood. J Gen Intern Med. 2008;23:1621–7.
18. Rosen DS, Blum RW, Britto M, Sawyer SM, Siegel DM. Transition to adult health care for adolescents and young adults with chronic conditions: position paper of the Society for Adolescent Medicine. J Adolesc Health. 2003;33:309–11.
19. Brown RT, editor. Comprehensive handbook of childhood cancer and sickle cell disease: a biopsychosocial approach. New York: Oxford University Press; 2006.
20. Nash KB, Telfair J. Sickle cell disease: a biopsychosocial model. In: Livingston I, editor. Handbook of Black American health: the mosaic of conditions, issues, policies, and prospects. Westport: Greenwood Press; 1994. p. 123–39.
21. Taylor LE, Stotts NA, Humphreys J, Treadwell MJ, Miaskowski C. A biopsychosocial-spiritual model of chronic pain in adults with sickle cell disease. Pain Manag Nurs. 2013;14:287–301.
22. Ballas SK, Kesen MR, Goldberg MF, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal. 2012;2012:949535.
23. Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010;85:6–13.
24. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303:1288–94.
25. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–78.
26. Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119:3925–32.
27. Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax. 2005;60:206–10.
28. Sharpe CC, Thein SL. Sickle cell nephropathy—a practical approach. Br J Haematol. 2011;155:287–97.
29. Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin N Am. 2005;19:917–28 (viii).
30. Porter JB, Evangeli M. Challenges of adherence and persistence with iron chelation therapy. Int J Hematol. 2011;94:453–60.
31. Chen E, Cole SW, Kato PM. A review of empirically supported psychosocial interventions for pain and adherence outcomes in sickle cell disease. J Pediatr Psychol. 2004;29:197–209.
32. Wang WC. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Curr Opin Hematol. 2007;14:191–7.
33. Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol. 2012;157:14–25.
34. Aygun B, Wruck LM, Schultz WH, et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. Am J Hematol. 2012;87:428–30.
35. NIH ends transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH) clinical trial due to early results. National Institutes of Health website. http://www.nih.gov/news/health/nov2014/nhlbi-19.htm. Accessed Dec 2, 2014.
36. Howard J, Woodhead T, Musumadi L, Martell A, Inusa BP. Moving young people with sickle cell disease from paediatric to adult services. Br J Hosp Med (Lond). 2010;71:310–4.
37. Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998;19:110–29.
38. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–94.
39. DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119:4587–96.
40. Pegelow CH, Macklin EA, Moser FG, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99:3014–8.
41. Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010;303:1823–31.
42. Kugler S, Anderson B, Cross D, et al. Abnormal cranial magnetic resonance imaging scans in sickle-cell disease. Neurological correlates and clinical implications. Arch Neurol. 1993;50:629–35.
43. Quinn CT, McKinstry RC, Dowling MM, et al. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2013;70:58–65.
44. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699–710.
45. Halfon N, Hochstein M. Life course health development: an integrated framework for developing health, policy, and research. Milbank Q. 2002;80:433–79 (iii).
46. King AA, Strouse JJ, Rodeghier MJ, et al. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014;89:162–7.
47. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2012;119:3684–90.
48. Dale JC, Cochran CJ, Roy L, Jernigan E, Buchanan GR. Health-related quality of life in children and adolescents with sickle cell disease. J Pediatr Health Care. 2011;25:208–15.
49. Telfair J, Myers J, Drezner S. Transfer as a component of the transition of adolescents with sickle cell disease to adult care: adolescent, adult, and parent perspectives. J Adolesc Health. 1994;15:558–65.
50. McPherson M, Thaniel L, Minniti CP. Transition of patients with sickle cell disease from pediatric to adult care: assessing patient readiness. Pediatr Blood Cancer. 2009;52:838–41.
51. Wojciechowski EA, Hurtig A, Dorn L. A natural history study of adolescents and young adults with sickle cell disease as they transfer to adult care: a need for case management services. J Pediatr Nurs. 2002;17:18–27.
52. Wilkie DJ, Johnson B, Mack AK, Labotka R, Molokie RE. Sickle cell disease: an opportunity for palliative care across the life span. Nurs Clin N Am. 2010;45:375–97.
53. Hauser ES, Dorn L. Transitioning adolescents with sickle cell disease to adult-centered care. Pediatr Nurs. 1999;25:479–88.
54. Eccleston C, Palermo TM, de C Williams AC, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2012;12:CD003968.
55. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156:415–9.
56. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115:5300–11.
57. Strouse JJ, Jordan LC, Lanzkron S, Casella JF. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol. 2009;84:548–52.
58. Liburd LC, Sniezek JE. Changing times: new possibilities for community health and well-being. Prev Chronic Dis. 2007;4:A73.
59. King AA, DeBaun MR, White DA. Need for cognitive rehabilitation for children with sickle cell disease and strokes. Expert Rev Neurother. 2008;8:291–6.
60. Bediako SM. Predictors of employment status among African Americans with sickle cell disease. J Health Care Poor Underserved. 2010;21:1124–37.
61. Key features of the Affordable Care Act by year. U.S. Department of Health & Human Services Web site. http://www.hhs.gov/healthcare/facts/timeline/timeline-text.html. Accessed Sept 18, 2014.
62. American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526–35.
63. Okumura MJ, Kerr EA, Cabana MD, Davis MM, Demonner S, Heisler M. Physician views on barriers to primary care for young adults with childhood-onset chronic disease. Pediatrics. 2010;125:e748–54.
64. Registry and surveillance system for hemoglobinopathies (RuSH). Centers for Disease Control and Prevention Web site. http://www.cdc.gov/ncbddd/hemoglobinopathies/documents/rushfactsheet2010.pdf. Accessed Oct 30, 2014.
65. National Institutes of Health, National Heart, Lung, and Blood Institute. The management of sickle cell disease. NIH Publication No. 02-2117; 2002.
66. Doulton DM. From cradle to commencement: transitioning pediatric sickle cell disease patients to adult providers. J Pediatr Oncol Nurs. 2010;27:119–23.
67. Jordan L. Day hospital reduces inpatient length of stay and emergency department visits for patients with sickle cell anemia. https://innovations.ahrq.gov/profiles/day-hospital-reduces-inpatient-length-stay-and-emergency-department-visits-patients-sickle.
68. American Academy of Pediatrics, American Academy of Family Physicians, and American College of Physicians, Transitions Clinical Report Authoring Group. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics. 2011;128:182–200.
69. Grosse SD, Schechter MS, Kulkarni R, Lloyd-Puryear MA, Strickland B, Trevathan E. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123:407–12.
70. Topic: sickle cell disease. National Institute for Children’s Health Quality Web site. http://www.nichq.org/sitecore/content/sickle-cell-disease/sickle-cell-disease. Accessed 24 Mar 2015.